O
ADAG

OrbiMed’s Adagene ADAG Stock Holding History

OrbiMed’s Portfolio ADAG Stock Details ADAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-263,176
Closed -$2.12M – 144
2021
Q4 		$2.12M Sell
263,176
-11,824
-4% -$121K 0.03% 150
2021
Q3 		$3.95M Hold
275,000
– – 0.04% 157
2021
Q2 		$3.73M Hold
275,000
– – 0.04% 151
2021
Q1 		$4.94M Buy
+275,000
New +$6.26M 0.05% 143

Other funds holding ADAG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SVI
Strategic Vision Investment Hong Kong $157M AUM 125.87% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

OrbiMed's ADAG Position: Q1 2022 in Review

OrbiMed sold out of Adagene (ADAG) in Q1 2022, closing a stake of 263,176 shares — an estimated $2.12M sold.

OrbiMed first reported a position in ADAG in Q1 2021 and held it in 4 quarters. The position peaked at $4.94M in Q1 2021. 15 funds tracked by Wall St. Rank hold ADAG as of Q1 2022.

  • OrbiMed reported no remaining Adagene position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 263,176 Adagene shares in Q1 2022, an estimated $2.12M.
  • OrbiMed first reported a position in Adagene in Q1 2021 and held it in 4 quarters.
  • OrbiMed's Adagene position peaked at $4.94M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Adagene as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.